Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Market Insight - Differentiation guiding firms through maze of hepatitis C drug development

This article was originally published in Scrip

Executive Summary

The therapeutic landscape in HCV treatment is at an inflection point – recent data from the first generation of protease inhibitors promise the dawn of a new standard of care. But do not expect to see a "winner takes all" market, say Paul Zhang, Dr Behrad Derakhshan and Dr David Muccino. Instead, individualised therapy will allow clinicians to tailor HCV management based on patient profiles and viral response.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts